Cantor Fitzgerald Keeps a Hold Rating on Verastem

By Ryan Adsit

In a report released today, Mara Goldstein from Cantor Fitzgerald reiterated a Hold rating on Verastem (NASDAQ: VSTM), with a price target of $2. The company’s shares closed yesterday at $2.12.

According to, Goldstein is ranked 0 out of 5 stars with an average return of -5.1% and a 38.1% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Corvus Pharmaceuticals Inc, and Karyopharm Therapeutics.

Currently, the analyst consensus on Verastem is Moderate Buy and the average price target is $3.80, representing a 79.2% upside.

In a report issued on May 24, Jefferies also reiterated a Hold rating on the stock with a $1.50 price target.

The company has a one year high of $2.54 and a one year low of $1.05. Currently, Verastem has an average volume of 515.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Verastem, Inc. is a clinical biopharmaceutical company, which is focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. The company is developing small molecule inhibitors of signaling pathways which includes Focal Adhesion Kinase FAK, PI3K/mTOR and Wnt that are critical to cancer stem cell survival and proliferation. Verastem was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg and Christoph H. Westphal on August 4, 2010 and is headquartered in Cambridge, MA.